AU2019257728A1 - ABCB5 ligands and substrates - Google Patents

ABCB5 ligands and substrates Download PDF

Info

Publication number
AU2019257728A1
AU2019257728A1 AU2019257728A AU2019257728A AU2019257728A1 AU 2019257728 A1 AU2019257728 A1 AU 2019257728A1 AU 2019257728 A AU2019257728 A AU 2019257728A AU 2019257728 A AU2019257728 A AU 2019257728A AU 2019257728 A1 AU2019257728 A1 AU 2019257728A1
Authority
AU
Australia
Prior art keywords
abcb5
pip2
composition
pathway
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2019257728A
Other languages
English (en)
Inventor
Markus H. Frank
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Childrens Hospital
Original Assignee
Boston Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Childrens Hospital filed Critical Boston Childrens Hospital
Publication of AU2019257728A1 publication Critical patent/AU2019257728A1/en
Priority to AU2025201810A priority Critical patent/AU2025201810A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/117—Esters of phosphoric acids with cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
AU2019257728A 2018-04-25 2019-04-25 ABCB5 ligands and substrates Abandoned AU2019257728A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025201810A AU2025201810A1 (en) 2018-04-25 2025-03-13 Abcb5 ligands and substrates

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662670P 2018-04-25 2018-04-25
US62/662,670 2018-04-25
PCT/US2019/029235 WO2019210109A1 (en) 2018-04-25 2019-04-25 Abcb5 ligands and substrates

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025201810A Division AU2025201810A1 (en) 2018-04-25 2025-03-13 Abcb5 ligands and substrates

Publications (1)

Publication Number Publication Date
AU2019257728A1 true AU2019257728A1 (en) 2020-11-12

Family

ID=68295729

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2019257728A Abandoned AU2019257728A1 (en) 2018-04-25 2019-04-25 ABCB5 ligands and substrates
AU2025201810A Pending AU2025201810A1 (en) 2018-04-25 2025-03-13 Abcb5 ligands and substrates

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025201810A Pending AU2025201810A1 (en) 2018-04-25 2025-03-13 Abcb5 ligands and substrates

Country Status (10)

Country Link
US (1) US12448461B2 (https=)
EP (1) EP3784249A4 (https=)
JP (2) JP7611701B2 (https=)
KR (2) KR102928177B1 (https=)
CN (1) CN112423765A (https=)
AU (2) AU2019257728A1 (https=)
CA (1) CA3097875A1 (https=)
MX (1) MX2020011297A (https=)
SG (1) SG11202010260XA (https=)
WO (1) WO2019210109A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
CN111007240A (zh) * 2019-12-02 2020-04-14 中国医学科学院北京协和医院 一种基于crispr技术的均相酶免疫检验系统及其方法和应用
CN115835882A (zh) * 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
CN113082210B (zh) * 2021-03-09 2023-04-18 广州白云山医药集团股份有限公司白云山制药总厂 一种肿瘤化疗药物组合物
CN116445573A (zh) * 2022-08-30 2023-07-18 苏州大学 一种以抑制trim54泛素化降解stat2为靶点的抗病毒ade药物筛选方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3587465T2 (de) 1984-09-10 1994-01-20 Hsc Res Dev Corp Vielfache Drogen-Resistenz in Säugetierzellinien und Isolierung der determinanten Glykoprotein-DNS.
US5837258A (en) 1991-08-30 1998-11-17 University Of South Florida Induction of tissue, bone or cartilage formation using connective tissue growth factor
ES2329953T3 (es) 1996-04-19 2009-12-02 Osiris Therapeutics, Inc. Regeneracion e incremento de hueso utilizando celulas madre mesenquimales.
US6152142A (en) 1997-02-28 2000-11-28 Tseng; Scheffer C. G. Grafts made from amniotic membrane; methods of separating, preserving, and using such grafts in surgeries
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
CA2266805C (en) 1998-03-27 2015-04-28 An-Go-Gen Inc. Cell-based gene therapy in the treatment of pulmonary disorders
AU2999199A (en) 1998-04-03 1999-10-25 Osiris Therapeutics, Inc. Mesenchymal stem cells as immunosuppressants
PT1082410E (pt) 1998-05-29 2007-11-09 Osiris Therapeutics Inc Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+
JP2003510071A (ja) 1999-09-28 2003-03-18 ジェンテスト・コーポレーション Ｐ−糖タンパク質およびその使用
US6673606B1 (en) 2000-04-12 2004-01-06 The Children's Hospital Of Philadelphia Therapeutic uses for mesenchymal stromal cells
CA2411101C (en) 2000-06-05 2018-01-16 Brigham And Women's Hospital, Inc. A gene encoding a multidrug resistance human p-glycoprotein homologue on chromosome 7p15-21 and uses thereof
US20040175366A1 (en) 2003-03-07 2004-09-09 Acell, Inc. Scaffold for cell growth and differentiation
EP1702061A4 (en) 2003-11-24 2007-05-02 Univ Rockefeller METHOD OF INSULATING A SELF-RENEWING, MULTIPOTENTIAL, SLOWLY CIRCULATING CELL
US20050186672A1 (en) 2004-01-27 2005-08-25 Reliance Life Sciences Pvt. Ltd. Tissue system with undifferentiated stem cells derived from corneal limbus
WO2006103685A2 (en) 2005-03-28 2006-10-05 Vision Research Foundation A method for cultivating cells derived from corneal limbal tissue and cells deived from corneal limbal tissue
KR101441843B1 (ko) 2005-10-18 2014-09-17 내셔날 쥬이쉬 헬스 조건부 불멸화 장기 줄기 세포 및 상기 세포의 제조 및 사용 방법
WO2007112097A2 (en) 2006-03-24 2007-10-04 Children's Medical Center Corporation Novel signature self renewal gene expression programs
GB0610778D0 (en) 2006-05-31 2006-07-12 Het Nl Kanker I Phosphatidylinositol phospahte and apoptosis
SI2772535T1 (sl) 2006-05-31 2022-08-31 Children's Medical Center Corporation ABC5 pozitivne mezenhimske matične celice kot imunomodulatorji
WO2008013492A1 (en) 2006-07-28 2008-01-31 Chundsell Medicals Ab Embryonic stem cell markers for cancer diagnosis and prognosis
WO2008064244A2 (en) 2006-11-20 2008-05-29 The Trustees Of Columbia University In The City Of New York Phosphoinositide modulation for the treatment of neurodegenerative diseases
EP2155248B1 (en) 2007-04-12 2015-06-10 The Brigham and Women's Hospital, Inc. Targeting abcb5 for cancer therapy
US9011840B2 (en) 2008-03-14 2015-04-21 The Board Of Trustees Of The University Of Illinois Activated mesenchymal stem cells for wound healing and impaired tissue regeneration
EP3978928A1 (en) 2008-11-14 2022-04-06 The Brigham and Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
US11542328B2 (en) 2008-11-14 2023-01-03 The Brigham And Women's Hospital, Inc. Therapeutic and diagnostic methods relating to cancer stem cells
WO2010065711A1 (en) * 2008-12-04 2010-06-10 Adimab, Inc. An abcb5 epitope and antibodies thereto for the treatment of cancer
KR101138091B1 (ko) 2011-08-31 2012-04-24 세원셀론텍(주) 중간엽 줄기세포 기본 배양 배지 조성방법, 중간엽 줄기세포 기본 배양 배지 및 이를 이용하여 배양분화된 세포치료제
WO2014130518A1 (en) 2013-02-19 2014-08-28 Children's Medical Center Corporation Abcb5(+) stem cells for treating ocular disease
AU2014262590B2 (en) 2013-05-10 2018-05-10 Children's Medical Center Corporation Wound healing and tissue engineering
WO2016179576A1 (en) * 2015-05-07 2016-11-10 Bioxcel Corporation Novel immunomodulatory therapeutic strategies targeting tumors in cancer
WO2016184793A1 (en) * 2015-05-15 2016-11-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for treating a patient with vegfr inhibitor-resistant metastatic renal cell carcinoma
ES2905558T3 (es) 2015-11-13 2022-04-11 Avellino Lab Usa Inc Procedimientos para el tratamiento de las distrofias corneales
WO2018185584A1 (en) 2017-04-05 2018-10-11 Pluristem Ltd. Methods and compositions for treating acute lung injury and respiratory distress syndrome
US20220184136A1 (en) 2019-03-28 2022-06-16 Children's Medical Center Corporation Highly functional manufactured abcb5+ mesenchymal stem cells
AU2020368845A1 (en) 2019-10-18 2022-05-12 Amniotics Ab Processes and apparatuses for obtaining amniotic mesenchymal stem cells from amniotic fluid and cells derived thereof
EP4125960A4 (en) 2020-03-30 2024-04-03 Children's Medical Center Corporation USING STEM CELLS TO TREAT EXCESSIVE INFLAMMATION
CN115835882A (zh) 2020-04-15 2023-03-21 儿童医学中心公司 靶向多形性胶质母细胞瘤中的abcb5
AU2021262864A1 (en) 2020-04-30 2022-11-17 Children's Medical Center Corporation Antibodies specific to ABCB5 and uses thereof

Also Published As

Publication number Publication date
JP2021522266A (ja) 2021-08-30
CN112423765A (zh) 2021-02-26
US20210188999A1 (en) 2021-06-24
US12448461B2 (en) 2025-10-21
MX2020011297A (es) 2020-11-18
SG11202010260XA (en) 2020-11-27
EP3784249A4 (en) 2022-03-02
KR102928177B1 (ko) 2026-02-20
KR20210005118A (ko) 2021-01-13
AU2025201810A1 (en) 2025-04-03
EP3784249A1 (en) 2021-03-03
JP2024154382A (ja) 2024-10-30
JP7611701B2 (ja) 2025-01-10
CA3097875A1 (en) 2019-10-31
WO2019210109A1 (en) 2019-10-31
KR20260025888A (ko) 2026-02-24

Similar Documents

Publication Publication Date Title
KR102928177B1 (ko) Abcb5 리간드 및 기질
TWI775781B (zh) 癌症之治療性及診斷性方法
KR101689946B1 (ko) 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
US20210290620A1 (en) Combinations of RET Inhibitors and mTORC1 Inhibitors and Uses Thereof for the Treatment of Cancer Mediated by Aberrant RET Activity
AU2014368912B2 (en) Cancer treatments using combinations of type 2 MEK and ERK inhibitors
JP2018521019A (ja) 抗ｏｘ４０抗体を使用して癌を治療する方法
KR20210034613A (ko) 퀴놀린 유도체 및 항체의 약물 조합
HUE032754T2 (en) CSF-1R inhibitors for the treatment of brain tumors
Garona et al. Preclinical efficacy of [V4Q5] dDAVP, a second generation vasopressin analog, on metastatic spread and tumor-associated angiogenesis in colorectal cancer
KR20170005419A (ko) Pi3k 억제제 피크틸리시브로 pr-양성 내강 a형 유방암을 치료하는 방법
WO2019178438A1 (en) Abbv-621 in combination with anti-cancer agents for the treatment of cancer
US20230136997A1 (en) Targeting abcb5 in glioblastoma multiforme
KR102558988B1 (ko) 항암제 내성을 완화하고 항암제의 민감성을 강화하기 위한 약학적 조성물 및 그 용도
CN115518162B (zh) 抗pd-1抗体和细胞毒类抗癌药在治疗非小细胞肺癌中的用途
CN115955962B (zh) 用于治疗淋巴肿瘤的沙铂
HK40047709A (en) Abcb5 ligands and substrates
TWI670079B (zh) 用於對抗具抗藥性癌症之組合物及方法
EP3160591A1 (en) Compositions and methods for treating cancer
WO2010096289A2 (en) Combination therapy using an anti-egfr agent(s) and igf-1r specific antibodies
HK40002960B (zh) 用於癌症的治疗和诊断方法
WO2010138362A1 (en) Combination therapy using an igf-1r specific antibody with an anti-egfr specific antibody and/or a cytotoxic agent

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted